Bluechiip Limited (ASX:BCT) Successfully Completes Share Purchase Plan
Bluechiip Limited (ASX:BCT) (FRA:1BL) is pleased to confirm the successful completion of its share purchase plan ("SPP") first announced on Friday, 5 May 2023, raising $727,500.
Companies in the News
Health & Pharm General
VIDEO: Proteomics International Laboratories Limited (ASX:PIQ) MD Dr. Richard Lipscombe Talks about the PromarkerD Test and Agreement with Sonic Healthcare
In this interview, Dr. Richard Lipscombe, Managing Director of Proteomics International Laboratories Limited (ASX:PIQ), talks about the agreement recently entered into with Sonic Healthcare (USA).
Proteomics International Laboratories Ltd (ASX:PIQ) Sonic Healthcare USA Signs Licence for PromarkerD in the US
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce it has signed an exclusive licence agreement with Sonic Healthcare USA, a Division of Sonic Healthcare Ltd.
Bluechiip Limited (ASX:BCT) Raises $2.2M and Announces Share Purchase Plan
Bluechiip Limited (ASX:BCT) (FRA:1BL), a leader in the development of advanced sample management solutions for harsh environments, today announced it has successfully raised $2.2 million via a placement to institutional, sophisticated and professional investors.
Proteomics International Laboratories Ltd (ASX:PIQ) World Endometriosis Congress - New Diagnostic Test Showcased
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce it will present its potential new blood test for endometriosis at the world's leading endometriosis conference.
VIDEO: Apiam Animal Health Limited (ASX:AHX) Managing Director Dr. Chris Richards Speaks with ABN Newswire About 3rd Quarter Results
Apiam Animal Health Limited (ASX:AHX) Managing Director Dr. Chris Richards outlines the Apiam brand and growing business, with veterinary practices joining the Apiam brand.
Proteomics International Laboratories Ltd (ASX:PIQ) Diabetes Drug, Canagliflozin, Lowers PromarkerD Diabetic Kidney Disease Risk Prediction Scores
Proteomics International Laboratories Ltd (ASX:PIQ) in collaboration with Janssen Research & Development have shown that treatment with Canagliflozin lowers the PromarkerD risk score for developing diabetic kidney disease.
Health & Pharm General Next Page▸
Banking & Finance
- NSX Limited (ASX:NSX) Quarterly Activities Report
- OTC Markets Group Welcomes CSL Limited (ASX:CSL) to OTCQX
- Inner East Community Finance Limited (NSX:IEC) Acquisition of Banking Book update - Kew East
Oil Gas & Energy
- Cobalt Blue Holdings Limited (ASX:COB) Investor Webinar
- Cobalt Blue Holdings Limited (ASX:COB) DFS Update
- Vintage Energy Ltd (ASX:VEN) Successful Completion of Institutional Placement
Life Sciences
- VIDEO: Proteomics International Laboratories Limited (ASX:PIQ) MD Dr. Richard Lipscombe Talks about the PromarkerD Test and Agreement with Sonic Healthcare
- BPH Energy Limited (ASX:BPH) Results of Loyalty Option Offer
- BPH Energy Limited (ASX:BPH) Investee Cortical Dynamics Update
Social Media
